Pharma Focus Asia

RadioMedix and Orano Moed Discovered Novel AlphaMedixTM for Gastroenteropancreatic Neuroendocrine Tumours

RadioMedix and Orano Moed have jointly developed a groundbreaking treatment named AlphaMedix™ (212Pb-DOTAMTATE) for adults with unresectable or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs) expressing somatostatin receptors who have not undergone peptide receptor radionuclide therapy (PRRT) before.

Targeted alpha therapy (TAT) operates on a fundamental principle: merging the targeting precision of biological molecules with the potent cell-killing abilities of alpha-emitting radioisotopes.

Alpha decay involves the emission of a helium nucleus (alpha particle) with high linear energy transfer, causing irreparable DNA damage in nearby cancer cells while sparing healthy tissue. This selective approach enhances the therapy's efficacy while reducing side effects.

AlphaMedix™, currently in Phase 2 clinical trials, utilises an SSTR-targeting peptide complex labelled with lead-212 (212Pb) to generate alpha particles in vivo. The short range and high energy of alpha particles enable precise targeting of cancer cells, offering a promising alternative to PRRT with beta-particle emitters for patients with metastatic or inoperable SSTR-expressing GEP-NETs.

Neuroendocrine tumours (NETs) are rare neoplasms originating from neuroendocrine cells, predominantly found in the gastrointestinal tract and pancreas (GEP-NETs). Although they can occur in various tissues, GEP-NETs pose significant clinical challenges due to their metastatic potential and limited treatment options.

RadioMedix and Orano Moed have been granted FDA breakthrough therapy designation for AlphaMedix™ in the treatment of gastroenteropancreatic neuroendocrine tumours.
 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference